Back

Galapagos N.V.

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

  • Registration date 25 may 2016 - 22:00
  • Statutory name Galapagos N.V.
  • Title FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016
  • Comments Mechelen, Belgium; 25 May 2016, 22.00 CET: Galapagos (Euronext & NASDAQ: GLPG) announces the presentation of detailed results from the Phase 2 FITZROY study of filgotinib in Crohn's Disease, at Digestive Disease Week (DDW[1]) 2016 in San Diego, CA, USA, held from 21-24 May. More information can be found at www.ddw.org.

Related downloads

201605250000000015_FITZROY F2 studie in Crohn 'late breaker' op DDW.pdf
201605250000000015_FITZROY Ph2 study in CD late breaker at DDW.pdf

Date last update: 28 January 2021

Share information

Share on: Share this